Equifax (EFX)
NYSEIndustrialsConsulting ServicesSnapshot 2026-07-08
$167.10-4.28%
Close 2026-07-08 · 1-day change
Reading EFX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EFX free→NYSEIndustrialsConsulting ServicesSnapshot 2026-07-08
Reading EFX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EFX free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable compounder with a focus on maintaining revenue growth. The current thesis state is intact, supported by strong recent financial performance.
The market currently reflects a neutral valuation for EFX, with expectations slightly below peers. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news at this time.
Management is on track to meet its revenue growth guidance for 2026, with recent results showing strong performance. However, there is a low probability of missing expectations, but caution is warranted due to recent misses in the industry.
The thesis hinges on the performance of sector bellwethers like VRSK, BAH, and FCN. If these companies continue to perform well, it could support EFX's momentum, while any negative shifts could pose risks.
In the next 1 to 3 years, EFX appears to be well-positioned, but external factors could influence its trajectory. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat, which indicates strong financial performance. There are no significant threats noted that could weaken this positive outlook.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This could show a slowdown in Equifax's growth. It may affect investor confidence.
Confirms:Q2 2026 reported revenue growth comes in below 9.3%.
Disproves:Q2 2026 revenue growth exceeds 11.3%.
Why it matters: Equifax keeps its revenue growth guidance. This shows it can handle market challenges. It shows confidence in future performance.
Confirms:Equifax maintains Q2 2026 revenue growth guidance of 9.3% to 11.3%.
Disproves:Equifax lowers Q2 2026 revenue growth guidance below 9.3%.
Why it matters: Higher cash returns show strong free cash flow. This means good capital allocation.
Confirms:Equifax returns more than $360 million to shareholders in Q2 2026.
Disproves:Cash returned to shareholders is less than $300 million in Q2 2026.
Why it matters: Better sector performance could help Equifax grow and reach revenue goals.
Confirms:Sector growth speeds up to nearly 10% year over year.
Disproves:Sector growth remains below 5% year over year.
Why it matters: A good surprise would show better performance and help revenue growth.
Confirms:Q2 earnings exceed analyst expectations by more than 5%.
Disproves:Q2 earnings are lower than what analysts expected.
Why it matters: Completing this change is important. It helps with how money is used and gives more flexibility.
Confirms:The credit agreement change is now complete.
Disproves:No announcement of completion by the next earnings date.
Why it matters: This growth rate is key to maintaining the 2026 revenue growth guidance. It shows if the company is on track.
Confirms:Q2 revenue growth meets or exceeds 5% year over year.
Disproves:Q2 revenue growth falls below 5% year over year.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Stabilization in U.S. Mortgage revenue is key to Equifax's overall growth. It signals resilience in a challenging market.
Confirms:U.S. Mortgage revenue growth stabilizes at or above 20% in Q2 2026.
Disproves:U.S. Mortgage revenue growth drops below 20% in Q2 2026.
Why it matters: The Vitality Index reflects the success of new products. A strong index supports growth and innovation efforts.
Confirms:Vitality Index exceeds 17% in Q2 2026.
Disproves:Vitality Index falls below 17% in Q2 2026.